×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARVN – arvinas, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARVN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/19
11:47 am
arvn
Arvinas (ARVN) had its price target raised by Citigroup Inc. from $18.00 to $21.00. They now have a "buy" rating on the stock.
Medium
Report
Arvinas (ARVN) had its price target raised by Citigroup Inc. from $18.00 to $21.00. They now have a "buy" rating on the stock.
3/19
08:52 am
arvn
Arvinas (ARVN) had its price target raised by BTIG Research from $14.00 to $16.00. They now have a "buy" rating on the stock.
Medium
Report
Arvinas (ARVN) had its price target raised by BTIG Research from $14.00 to $16.00. They now have a "buy" rating on the stock.
3/18
03:01 pm
arvn
Arvinas (ARVN) was given a new $10.00 price target by Truist Financial Corporation.
Low
Report
Arvinas (ARVN) was given a new $10.00 price target by Truist Financial Corporation.
3/18
07:40 am
arvn
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days [Yahoo! Finance]
Medium
Report
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days [Yahoo! Finance]
3/18
07:00 am
arvn
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
High
Report
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
3/11
08:04 pm
arvn
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference [Yahoo! Finance]
Medium
Report
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference [Yahoo! Finance]
3/11
07:37 am
arvn
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders [Yahoo! Finance]
Low
Report
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders [Yahoo! Finance]
3/11
07:00 am
arvn
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Low
Report
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/26
03:44 pm
arvn
Form SCHEDULE 13G/A ARVINAS, INC. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A ARVINAS, INC. Filed by: VANGUARD GROUP INC
3/19
08:02 pm
arvn
Form 4 ARVINAS, INC. For: Mar 18 Filed by: Berkowitz Noah
Low
Report
Form 4 ARVINAS, INC. For: Mar 18 Filed by: Berkowitz Noah
3/18
07:07 am
arvn
Form 8-K ARVINAS, INC. For: Mar 18
High
Report
Form 8-K ARVINAS, INC. For: Mar 18
3/17
07:25 pm
arvn
Form 144 ARVINAS, INC. Filed by: Berkowitz Noah
Medium
Report
Form 144 ARVINAS, INC. Filed by: Berkowitz Noah
3/12
05:41 pm
arvn
Form 4/A ARVINAS, INC. For: Feb 26 Filed by: Teel Randy
Low
Report
Form 4/A ARVINAS, INC. For: Feb 26 Filed by: Teel Randy
3/9
04:05 pm
arvn
Form 4 ARVINAS, INC. For: Mar 06 Filed by: Morrison Briggs
Low
Report
Form 4 ARVINAS, INC. For: Mar 06 Filed by: Morrison Briggs
3/2
09:01 pm
arvn
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Loomis David K
Low
Report
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Loomis David K
3/2
09:00 pm
arvn
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Berkowitz Noah
Low
Report
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Berkowitz Noah
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Form S-8 ARVINAS, INC.
18.8%
11/6 Form 424B5 ARVINAS, INC. 15.1%
6/4 Bayer teams up with biotech firm Arvinas in deal worth up to $750 million [Reuters (UK)] 11.3%
10/23 Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders 10.5%
11/27 Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference 8.8%
3/24 Form 4 ARVINAS, INC. For: Mar 23 Filed by: Houston John G 7.4%
7/25 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk 7.3%
11/12 Form 8-K ARVINAS, INC. For: Nov 06 6.9%
7/25 Form 8-K ARVINAS, INC. For: Jul 24 5.9%
9/12 Arvinas Inc (NASDAQ: ARVN) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating on the stock. 5.8%
11/6 Form 424B5 ARVINAS, INC. 15.1%
6/4 Bayer teams up with biotech firm Arvinas in deal worth up to $750 million [Reuters (UK)] 11.3%
10/23 Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders 10.5%
11/27 Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference 8.8%
3/24 Form 4 ARVINAS, INC. For: Mar 23 Filed by: Houston John G 7.4%
7/25 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk 7.3%
11/12 Form 8-K ARVINAS, INC. For: Nov 06 6.9%
7/25 Form 8-K ARVINAS, INC. For: Jul 24 5.9%
9/12 Arvinas Inc (NASDAQ: ARVN) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating on the stock. 5.8%
TOP News Decliners
3/16
Q4/2019 12/31/2019 EPS -0.560 ZacksConsensus N/A ActVsEst N/A - N/A
-18.4%
3/20 Form 4 ARVINAS, INC. For: Mar 18 Filed by: Margus Bradley Albert -11.5%
8/22 Arvinas Inc (NASDAQ: ARVN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.3%
8/5 Q2/2019 6/30/2019 EPS -0.550 ZacksConsensus N/A ActVsEst N/A - N/A -7.9%
10/1 Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio -7.1%
3/10 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $52.00 price target on the stock. -7.1%
2/6 Form 8-K ARVINAS, INC. For: Jan 31 -6.3%
7/31 Form 3 ARVINAS, INC. For: Jul 29 Filed by: Peck Ronald -5.1%
7/16 Form 8-K ARVINAS, INC. For: Jul 15 -4.8%
10/7 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.5%
3/20 Form 4 ARVINAS, INC. For: Mar 18 Filed by: Margus Bradley Albert -11.5%
8/22 Arvinas Inc (NASDAQ: ARVN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.3%
8/5 Q2/2019 6/30/2019 EPS -0.550 ZacksConsensus N/A ActVsEst N/A - N/A -7.9%
10/1 Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio -7.1%
3/10 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $52.00 price target on the stock. -7.1%
2/6 Form 8-K ARVINAS, INC. For: Jan 31 -6.3%
7/31 Form 3 ARVINAS, INC. For: Jul 29 Filed by: Peck Ronald -5.1%
7/16 Form 8-K ARVINAS, INC. For: Jul 15 -4.8%
10/7 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: